TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01460823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Cochlear Implantation using image guided surgical techniques
Description: Percutaneous Cochlear Implantation using image guided surgical techniques.
Study: NCT03442634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Hydration
Description: this group will start oral hydration within 1 hour after cesarean section

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Oral Hydration
Description: this group will start oral hydration 6 hours after cesarean section
Study: NCT01851408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temsirolimus
Description: Given IV
Study: NCT02776241

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: water
Study: NCT03676127

Intervention type: OTHER
Intervention: ultrasonographic dermal thickness measurements
Description: ultrasonographic dermal thickness measurements
Study: NCT00670410

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Related donor transplant
Description: Patients with a related donor will get reduced intensity transplant conditioning with busulfan and fludarabine.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord blood transplant
Description: Patients with a matched cord blood donor will get reduced intensity conditioning with busulfan, fludarabine, and ATG.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan (Busulfex) \[4mg/kg/dose for patients \< 4 years; 3.2 mg/kg/dose for patients \> 4 years\] will be given IV in 0.9% sodium chloride or D5W to a final concentration \> 0.5 mg/mL solution for infusion equal to 10 times the volume of diluent to Busulfex, through a central venous access device over 3 hours once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan (Busulfex) \[4mg/kg/dose for patients \< 4 years; 3.2 mg/kg/dose for patients \> 4 years\] will be given IV in 0.9% sodium chloride or D5W to a final concentration \> 0.5 mg/mL solution for infusion equal to 10 times the volume of diluent to Busulfex, through a central venous access device over 3 hours once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: Patients with an umbilical cord blood donor will also receive Thymoglobulin (ATG-rabbit) during the preparative regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 x 5 days, total dose = 150 mg/m2. Patients \< 12 kg will receive Fludarabine 1 mg/kg x 5 days, total dose = 5 mg/kg. Fludarabine will be given IV in 100 ml (or to a concentration of 1 mg/mL) of D5W or 0.9% sodium chloride, and infused over 30 min on Days -6 to 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30 mg/m2 x 5 days, total dose = 150 mg/m2. Patients \< 12 kg will receive Fludarabine 1 mg/kg x 5 days, total dose = 5 mg/kg. Fludarabine will be given IV in 100 ml (or to a concentration of 1 mg/mL) of D5W or 0.9% sodium chloride, and infused over 30 min on Days -6 to 2.
Study: NCT03720132

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extensive flushing of the port catheter
Description: The port catheter will be flushed extensively with sodium chloride 0.9% before blood sampling. Blood sampling will occur through the central catheter and peripherally simultaneously.
Study: NCT02441504

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity Exercise
Description: aerobic exercise training using walking and running
Study: NCT00356031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
Study: NCT00305942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Topotecan 4mg/m2 IV on days 1, 8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin AUC=5 IV day 1 only .
Study: NCT04575701

Intervention type: OTHER
Intervention: TNF Alpha therapy
Description: Retrospective analysis of outcome of first TNF Alpha therapy

Intervention type: OTHER
Intervention: TNF Alpha therapy
Description: Retrospective analysis of outcome of first TNF Alpha therapy

Intervention type: OTHER
Intervention: TNF Alpha therapy
Description: Retrospective analysis of outcome of first TNF Alpha therapy
Study: NCT03317951

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Novel integrated care concept (NICC)
Description: Integrated care concept including, e.g., call center, guideline therapy, tablet and medical devices

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Guideline therapy according to the guidelines of the European Society of Cardiology (ESC).
Study: NCT02312947

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: coblation (COBLATION II surgery system ,CE8001-01)
Description: comparison of two methods of operation : coblation and cold dissection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cold dissection adenoidectomy
Description: comparison of two methods of operation : coblation and cold dissectionby currete
Study: NCT03147469

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flexion
Description: After changing the position of head and neck of subjects to flexion, the variables were measured.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extension
Description: After changing the position of head and neck of subjects to extension, the variables were measured.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Right rotation
Description: After changing the position of head and neck of subjects to right flexion, the variables were measured.
Study: NCT02100605

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phytosun, decongestant, nasal spray
Description: one time application of the nasal spray

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Phytosun, decongestant, nasal spray
Description: one time application of the nasal spray
Study: NCT03338660

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of Platelets
Description: Platelets will be stored using novel, FDA approved, technique. Subjects will receive infusion of platelets stored by novel technique, routine storage, and placebo (saline).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infusion of Platelets
Description: Platelets will be stored using the routine platelet storage method. Subjects will receive infusion of platelets stored by routine storage method.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive infusion placebo (saline).
Study: NCT02178722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB024360
Description: Oral daily dosing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB024360
Description: Oral daily dosing
Study: NCT04192591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Superion™ IDS device
Description: The Superion™ IDS is a minimally-invasive spinal implant that treats LSS symptoms by limiting extension at the symptomatic level that compresses the neural elements and is designed for percutaneous surgical placement.
Study: NCT05340010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotrophin Intramuscular injection 10.000 IU
Description: From the 12th to 13th day of the cycle when endometrium reached the optimal thickness ≥8 mm, group 1 (hCG) will receive 10.000 IU hCG intramuscular injection in the morning then vaginal suppository progesterone 400 mg twice a day will be started in the afternoon
Study: NCT00440297

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: modified process hepatitis B vaccine
Description: Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: ENGERIX-B™
Description: ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
Study: NCT03012178

Intervention type: PROCEDURE
Intervention: Mitral valve surgery
Description: ACC/AHA guideline directed mitral valve repair or replacement
Study: NCT04558905

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face medical visits
Description: Face-to-face medical visits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alternating face-to-face medical visits and video medical consultations
Description: Alternating face-to-face medical visits and video medical consultations
Study: NCT03769285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Oral nicotinamide (500 mg) twice daily for at least 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Matching placebo taken twice daily for at least 52 weeks
Study: NCT05068609

Intervention type: BIOLOGICAL
Intervention: Nivolumab
Description: Participants in this study are being treated with nivolumab for SCCHN
Study: NCT02061852

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Simeox

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simeox
Study: NCT02877186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: commercially-available diet soda
Description: Subjects are asked to consume diet soda three times daily for one week.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: carbonated water (control)
Description: Subjects are asked to consume carbonated water three times daily for one week.
Study: NCT02005705

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient Management of Low-risk Patients
Description: * Labs will be obtained within 2-3 days of discharge from ED~* Clinic visit will be scheduled within 3 days of discharge from ED~* EGD will be scheduled within 7 days of discharge from ED~* Phone follow-up at day 7 and 30

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inpatient Management of Low-risk Patients
Description: * Labs will be obtained on day of discharge or day 2-3~* EGD will be performed in the hospital~* Phone follow-up at day 7 and 30
Study: NCT01762085

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nerve decompression
Description: surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
Study: NCT02061852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Study: NCT00783484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03716539
Description: PF-03716539 50 mg oral solution, single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam 1 mg IV, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam + PF-03716539 (100 mg)
Description: Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam + PF-03716539 (50 mg)
Description: Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir + PF-03716539
Description: Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
Study: NCT02758457

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dental crowns

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental crowns
Study: NCT00756938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
Study: NCT02771522

Intervention type: DEVICE
Group type: OTHER
Intervention: Calcivis System
Description: Following de-bond, and identification of active post-orthodontic white spot lesions at baseline with the Calcivis System, each active tooth will be again be imaged at 2, 4, 8 and 12 weeks. Both black \& white and luminescent images images of the teeth are taken. The images of each tooth are overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
Study: NCT00441545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosrenol (Lanthanum Carbonate)
Description: The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevelamer hydrochloride
Description: The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.
Study: NCT00598299

Intervention type: PROCEDURE
Intervention: venous puncture
Description: venous puncture

Intervention type: PROCEDURE
Intervention: venous puncture
Description: venous puncture

Intervention type: OTHER
Intervention: obtain serum from perripheral blood or cord blood
Description: obtain serum from perripheral blood or cord blood

Intervention type: OTHER
Intervention: obtain serum from perripheral blood or cord blood
Description: obtain serum from perripheral blood or cord blood
Study: NCT03437551

Intervention type: OTHER
Intervention: cross-sectional observation
Description: cross-sectional ophthalmic examination
Study: NCT00783484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
Study: NCT02213874

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire
Description: A questionnaire will be administered during the early stages of prenatal care \& again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy \& collect information about demographics, contraceptive \& reproductive history, future pregnancy intentions, \& baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy \& contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, \& the type of counseling received.
Study: NCT01717469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left ventricular pacing through coronary sinus tributaries (Attain StarFix)
Description: Left ventricular pacing in patients with bradycardia

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Right ventricular pacing (Medtronic)
Description: Conventional right ventricular pacing in patients with bradycardia.
Study: NCT03078465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Daily administration of ticagrelor 180mg for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Daily administration of clopidogrel 150mg for 12 months
Study: NCT03671928

Intervention type: OTHER
Group type: OTHER
Intervention: additional blood tube
Description: sampling of an additional tube at the usual blood test to determine the glicentin level

Intervention type: OTHER
Group type: OTHER
Intervention: additional blood tube
Description: sampling of an additional tube at the usual blood test to determine the glicentin level

Intervention type: OTHER
Group type: OTHER
Intervention: additional blood sample
Description: for le group control, another blood sample is taken outside the usual care.
Study: NCT00828282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
Study: NCT03539445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylphthalide
Description: This group will receive a 3-month regimen of Butylphthalide and Sodium Chloride Injection 100ml twice/day in the initial 14 days and Butylphthalide Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Butylphthalide Placebo
Description: This group will receive a 3-month regimen of Butylphthalide Placebo Injection 100ml twice/day in the initial 14 days and Butylphthalide Placebo Soft Capsules 0.2g triple/day for the rest Day 15 to Day 90.
Study: NCT04276207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered by CSII

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered by CSII
Study: NCT04297215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DermaCura® Chitosan based antimicrobial therapeutic clothing
Description: DermaCura® antimicrobial therapeutic clothing (D\&M) consists of 98% TENCEL® and 2% elastane. 1% chitosan has been added to TENCEL®~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Binamed® silver based antimicrobial therapeutic clothing
Description: The Binamed® antimicrobial therapeutic clothing (BAP Medical) consists of micro-modal, lycra and woven silver filaments as antibacterial agent.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Binamed® therapeutic clothing without antimicrobial agents
Description: The Binamed® therapeutic clothing without antimicriobial agents (BAP Medical) is therapeutic clothing made of micro-modal and lycra. Micro-madal is a semi-synthetic wood cellulose fiber. This fiber has a high strength hand elasticity, a high moisture-permeability and feels soft. Lycra ensures an optimal fit on the skin.~The therapeutic clothing is to be worn at night during the 12-month intervention period and if needed during the day. Usual care including application of emollients, corticosteroid ointments or creams only if needed and/or antihistamines is continued, with standardized steroid ointments and treatment regimens for comparability purposes.
Study: NCT03642145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort tablets will be administered as per schedule and dose specified in respective arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort
Description: Deflazacort tablets will be administered as per schedule and dose specified in respective arms.
Study: NCT01679041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4